Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;106(3):277-282.
doi: 10.1308/rcsann.2023.0004. Epub 2023 May 30.

Myocardial protection in paediatric cardiac surgery: building an evidence-based strategy

N E Drury  1   2
Affiliations

Myocardial protection in paediatric cardiac surgery: building an evidence-based strategy

N E Drury. Ann R Coll Surg Engl. 2024 Mar.

Abstract

Cardioplegia is fundamental to the surgical repair of congenital heart defects by protecting the heart against ischaemia/reperfusion injury, characterised by low cardiac output and troponin release in the early postoperative period. The immature myocardium exhibits structural, physiological and metabolic differences from the adult heart, with a greater sensitivity to calcium overload-mediated injury during reperfusion. Del Nido cardioplegia was designed specifically to protect the immature heart, is widely used in North America and may provide better myocardial protection in children; however, it has not been commercially available in the UK, where most centres use St Thomas' blood cardioplegia. There are no phase 3 clinical trials in children to support one solution over another and this lack of evidence, combined with variations in practice, suggests the presence of clinical equipoise. The best cardioplegia solution for use in children, and the impact of age and other clinical factors remain unknown. In this Hunterian lecture, I propose an evidence-based strategy to improve myocardial protection during cardiac surgery in children through: (1) conducting multicentre clinical trials of established techniques; (2) improving our knowledge of ischaemia/reperfusion injury in the setting of cardioplegic arrest; (3) applying this to drive innovation, moving beyond current cardioplegia solutions; (4) empowering personalised medicine, through combining clinical and genomic data, including ethnic diversity; and (5) understanding the impact of cardioplegic arrest on the late outcomes that matter to patients and their families.

Keywords: Cardiac surgery; Cardioplegia; Children; Myocardial protection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical trials of cardioplegia published by year. PubMed® search (performed on 19 April 2022): cardioplegia [tiab]; limit: clinical trial; results by year; paediatric studies identified using the improved CCG child filter
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. National Institute for Cardiovascular Outcomes Research. National Congenital Heart Disease Audit (NCHDA): 2021 Summary Report. London: HQIP; 2021.
    1. Taggart DP, Hadjinikolas L, Hooper Jet al. . Effects of age and ischemic times on biochemical evidence of myocardial injury after pediatric cardiac operations. J Thorac Cardiovasc Surg 1997; 113: 728–735. - PubMed
    1. Mildh LH, Pettilä V, Sairanen HI, Rautiainen PH. Cardiac troponin T levels for risk stratification in pediatric open heart surgery. Ann Thorac Surg 2006; 82: 1643–1649. - PubMed
    1. Gaies M, Pasquali SK, Donohue JEet al. . Seminal postoperative complications and mode of death after pediatric cardiac surgical procedures. Ann Thorac Surg 2016; 102: 628–635. - PMC - PubMed
    1. Chen JM. Who makes the best martini? Semin Thorac Cardiovasc Surg 2017; 29: 375–376. - PubMed